MedTrace Logo

Plaquenil for Alopecia Areata, Alopecia Totalis

NCT00176982 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2009-08-13

No results posted yet for this study

Summary

Alopecia areata is an autoimmune condition resulting in hair loss and complete baldness (alopecia totalis). Published evidence says that it is mediated by T-lymphocytes. Plaquenil is an anti-inflammatory drug approved by the FDA for malaria, lupus erythematosus, and rheumatoid arthritis. It has an effect on T-lymphocyte mediated inflammation, making it a logical choice for a treatment trail for alopecia areata.

Conditions

Interventions

DRUG

Hydroxychloroquine

Sponsors & Collaborators

  • Hordinsky, Maria K., MD

    lead INDIV

Principal Investigators

  • Maria Hordinsky, MD · University of Minnesota

  • Richard Kalish, MD, PhD · State Universiyt of New York at Stony Brook

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-04-30
Primary Completion
2007-12-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00176982 on ClinicalTrials.gov